4 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 5 Phase 1, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 2 | 5 | Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Antigens: new trials by email Literature Review of Antigens trials Research Report on Antigens
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ), Shingles | Phase 2 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 840 | 2025-10-23 | 2025-12-30 |
| Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ) | Phase 1 | Recruiting | Guangzhou Patronus Biotech Co., Ltd. | 92 | 2025-03-13 | 2025-04-01 |
| Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer Autologous dendritic cells pulsed with antigen - NSCLC | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 30 | 2019-12-01 | 2019-12-16 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Recruiting | OHSU Knight Cancer Institute | 90 | 2019-08-01 | 2026-09-04 |
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| Food Antigen in Eosinophilic Esophagitis Antigen (wheat base soy sauce) spray - Eosinophilic Esophagitis | Completed | Mayo Clinic | 72 | 2015-04-01 | 2023-12-12 | |
| Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above Adjuvanted, trivalent subunit influenza vaccine, Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine, Antigen level modified adjuvanted, trivalent subunit influenza vaccine - Influenza | Phase 1 | Completed | Seqirus | 196 | 2014-06-01 | 2016-07-29 |
| A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Antigen (Ag85B-ESAT-6), Antigen (Ag85B-ESAT-6) with adjuvant (IC31) - Tuberculosis | Phase 1 | Completed | Statens Serum Institut | 39 | 2008-12-01 | 2015-04-17 |
| Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation - Influenza | Phase 1 / Phase 2 | Completed | Alachua Government Services, Inc. | 110 | 2007-07-01 | 2015-10-09 |
Chickenpox (2) · Herpes Zoster (2) · Influenza, Human (2) · Carcinoma, Hepatocellular (1) · Eosinophilic Esophagitis (1) · Pancreatic Neoplasms (1) · Squamous Intraepithelial Lesions (1) · Tuberculosis (1) · Uterine Cervical Dysplasia (1)
Guangzhou Patronus Biotech Co., Ltd. (2) · Alachua Government Services, Inc. (1) · Emory University (1) · Henan Cancer Hospital (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Seqirus (1) · Statens Serum Institut (1) · THEVAX Genetics Vaccine (1)
United States (4) · China (3) · Germany (1) · Hong Kong (1) · Singapore (1)
Charles D Lopez (1) · Frank L Douglas, PhD, MD (1) · Jemal Hussein, MD (1) · Joseph Murray, MD (1) · Olumide B. Gbolahan, MBBS, MSc (1) · Peter Bang, Msc (1) · Renfeng Fan (1) · Tao Huang (1) · Zibing Wang (1)
P30CA138292 (1)